Optimizing the Size and Improving the Impact of Oncology Field-Based Medical Teams in Major Global Markets: Thought Leader Engagement, Managing Field Activities & Productivity Levels

STUDY OVERVIEW

To maximize the impact of oncology-focused field-based medical teams in high-potential global markets, organizations need to be engaging Thought Leaders effectively and efficiently. Complicating an already difficult assignment, field teams must reflect the needs and opportunities of the region they work in.

Best Practices, LLC conducted this study to provide current oncology field team engagement practices in key markets. The study contains benchmarks around the duration and frequency of MSL and HOL interactions; the degree of proactive vs. reactive interactions; and the time spent on internal and external activities

This study will help companies fill knowledge gaps around MSL engagement trends for oncology-focused field medical teams. Leaders involved with field-based medical teams focused on oncology can utilize this study to compare their engagement approaches and metrics with peers in key markets.

This study includes four segments: All Participants, North America, Europe (Germany and UK), and global (countries outside the US).


KEY TOPICS

• Executive Summary: Methodology, Participants, & Key Findings
• Thought Leader Engagement
• Field Activities and Productivity Levels
  
  

• Total yearly MSL interactions with thought leaders
• Average time MSL/HOL spend on each F2F thought leader interaction
• What is the frequency, on average, that MSLs interact with these different thought leader types
• What is the frequency, on average, that HOLs interact with payers
• Percentage of MSL interactions with thought leaders that are proactive
• How often do your field MSLs conduct the following proactive activities
• How often do your field MSLs conduct the following reactive activities
• What percentage of thought leader interactions take place on each of these communication channels
• How effective are each of these communication channels with thought leaders
• How much time do your MSLs spend, on average, on these external activities each week
• What is the ideal time that MSLs should spend on these activities each week
  

• Proactive vs. Reactive MSL Interactions: Overall, 56% of MSL interaction are proactive vs. 44% reactive. The most common proactive activities (e.g., disease state discussion, on-label clinical study data and on-label product science) occur often and with approximately the same frequency across regions.

Twenty field-based medical leaders and medical affairs executives participated in this benchmark research. These leaders provided field performance data and qualitative insights from a total of 15 Oncology pharma and biotech organizations.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Manufacturing; Consumer Products; Diagnostic; Medical Device


Companies Profiled:
AstraZeneca; Daiichi Sankyo; Eisai; EMD Serono; Merck; Genentech; GlaxoSmithKline ; Shire; Janssen; Ipsen; Astellas; Amgen; Bayer; Roche; Merck Serono

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.